{"id":11242,"date":"2019-10-21T00:00:00","date_gmt":"2019-10-21T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/"},"modified":"2025-08-19T08:28:20","modified_gmt":"2025-08-19T13:28:20","slug":"nouvelle-recommandation-de-remboursement-pour-pomalyst","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/","title":{"rendered":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST"},"content":{"rendered":"<p>L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la l\u00e9nalidomine.<\/p>\n<p><a href=\"https:\/\/www.cadth.ca\/fr\/pomalidomide-pomalyst-en-association-avec-dexamethasone-et-bortezomib-dans-le-traitement-du-myelome?utm_source=CONS+List&amp;utm_campaign=dcda58cc00-pCODR-08-01-2019-final-recs_COPY_01&amp;utm_medium=email&amp;utm_term=0_f3b3313866-dcda58cc00-263006281\" target=\"_blank\" rel=\"noopener\">Voir les crit\u00e8res de remboursement<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11242","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2019-10-21T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:20+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#blogposting\",\"name\":\"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST | My\\u00e9lome Canada\",\"headline\":\"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2019-10-21T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:20-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, News &amp; Events, Nouvelles de My\\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#listItem\",\"name\":\"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#listItem\",\"position\":4,\"name\":\"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/\",\"name\":\"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST | My\\u00e9lome Canada\",\"description\":\"L\\u2019Agence canadienne des m\\u00e9dicaments et des technologies de la sant\\u00e9 a \\u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\\u00e9thasone et bort\\u00e9zomib, est maintenant indiqu\\u00e9 dans le traitement des patients adultes atteints de my\\u00e9lome multiple (MM) r\\u00e9cidivant ou r\\u00e9fractaire qui ont d\\u00e9j\\u00e0 re\\u00e7u au moins une forme de traitement comprenant la\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/10\\\/21\\\/nouvelle-recommandation-de-remboursement-pour-pomalyst\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2019-10-21T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:20-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST | My\u00e9lome Canada","description":"L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la","canonical_url":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#blogposting","name":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST | My\u00e9lome Canada","headline":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2019-10-21T00:00:00-05:00","dateModified":"2025-08-19T08:28:20-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, News &amp; Events, Nouvelles de My\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#listItem","name":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#listItem","position":4,"name":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/","name":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST | My\u00e9lome Canada","description":"L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2019-10-21T00:00:00-05:00","dateModified":"2025-08-19T08:28:20-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST | My\u00e9lome Canada","og:description":"L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la","og:url":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/","article:published_time":"2019-10-21T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:20+00:00","twitter:card":"summary_large_image","twitter:title":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST | My\u00e9lome Canada","twitter:description":"L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la"},"aioseo_meta_data":{"post_id":"11242","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 17:03:46","updated":"2026-04-30 07:29:56","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11242"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11242\/revisions"}],"predecessor-version":[{"id":31323,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11242\/revisions\/31323"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}